Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21889711 | 0.87 | KMT2A (0.34) | KMT2ARAB9ASMN1; SMN2ACKR3L3MBTL1 | |
| SCHEMBL24690684 | 0.86 | ALDH1A1 (0.43) | KMT2AACKR3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9005243 | 0.83 | EGFR (0.41) | ACKR3KDM4ECHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20939084 | 0.81 | ACKR3 (0.36) | ACKR3 | |
| SCHEMBL19069390 | 0.81 | ACKR3 (0.36) | ACKR3 | |
| SCHEMBL20938920 | 0.80 | ACKR3 (0.34) | ACKR3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL19069227 | 0.79 | ACKR3 (0.33) | ACKR3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL21889707 | 0.78 | CHRNB2 (0.33) | ACKR3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL22332213 | 0.77 | ALDH1A1 (0.38) | ACKR3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL22355637 | 0.77 | ACKR3 (0.30) | ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-10781207-B2 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | ISOCURE BIOSCIENCES INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-10653701-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190307767-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190233414-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC (US) | 2019-08-01 | — | — | US | disclosed |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307767-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | KMT2A 830/4885RAB9A 1145/4885SMN1; SMN2 3384/4885 |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | KMT2A 2717/4885RAB9A 1360/4885SMN1; SMN2 3736/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | KMT2A 830/4885RAB9A 2430/4885SMN1; SMN2 4194/4885 |
| US-10653701-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | KMT2A 830/4885RAB9A 1145/4885SMN1; SMN2 3384/4885 |
| US-10781207-B2 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | IDH1, IDH2, IDH3A | KMT2A 530/4885RAB9A 3547/4885SMN1; SMN2 2494/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | KMT2A 469/4885RAB9A 2726/4885SMN1; SMN2 2891/4885 |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KMT2A 3318/4885RAB9A 580/4885SMN1; SMN2 2352/4885 |
| US-20190233414-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | IDH1, IDH2, IDH3A | KMT2A 530/4885RAB9A 3547/4885SMN1; SMN2 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.